We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Effectiveness of Hyperbaric Oxygen Therapy in Question

By HospiMedica International staff writers
Posted on 12 Mar 2013
The use of Hyperbaric Oxygen Therapy (HBOT) for diabetic foot ulcers neither improved the likelihood that a wound would heal nor prevented amputation, according to a new study.

Researchers at the University of Pennsylvania (Philadelphia, USA) conducted a longitudinal observational cohort study to compare the effectiveness of HBOT with other conventional therapies for the treatment of a diabetic foot ulcer, and prevention of lower extremity amputation. More...
The authors studied 6,259 individuals with diabetes, adequate lower limb arterial perfusion, and foot ulcer extending through the dermis, representing 767,060 person-days of wound care. To address treatment selection bias, the authors used propensity scores to determine the tendency for selection of HBOT.

The results showed that in the propensity score-adjusted models, individuals receiving HBOT were less likely have healing of their foot ulcer and more likely to have an amputation. Additional analyses, including the use of an instrumental variable, were conducted to assess the robustness of the results to unmeasured confounding; HBOT was not found to improve the likelihood that a wound might heal or to decrease the likelihood of amputation in any of these analyses. The study was published on February 21, 2013, in Diabetes Care.

“HBOT did not appear to be useful for the prevention of amputation and did not improve the likelihood that a wound would heal in a cohort of patients defined by Centers for Medicare and Medicaid Services eligibility criteria,” concluded lead author David Margolis, MD, PhD, and colleagues of the department of dermatology.

HBOT involves the breathing of pure oxygen while in a sealed chamber that has been pressurized at 1.5 to 3.0 times normal atmospheric pressure. The first known chamber was built by a British clergyman named Henshaw in the 1600s. Research has shown HBOT can help when used as a mainstream treatment for the prevention and treatment of osteoradionecrosis, as well as more than a dozen health problems such as decompression sickness, carbon monoxide poisoning, gangrene, brain abscess, and injuries in which tissues are not getting enough oxygen.

Related Links:
University of Pennsylvania



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.